Cargando…

Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models

Nonalcoholic fatty liver disease (NAFLD) is a range of pathologies arising from fat accumulation in the liver in the absence of excess alcohol use or other causes of liver disease. Its complications include cirrhosis and liver failure, hepatocellular carcinoma, and eventual death. NAFLD is the most...

Descripción completa

Detalles Bibliográficos
Autores principales: Basha, Amina, May, Sarah C., Anderson, Ryan M., Samala, Niharika, Mirmira, Raghavendra G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298283/
https://www.ncbi.nlm.nih.gov/pubmed/37373143
http://dx.doi.org/10.3390/ijms24129996
_version_ 1785064076962955264
author Basha, Amina
May, Sarah C.
Anderson, Ryan M.
Samala, Niharika
Mirmira, Raghavendra G.
author_facet Basha, Amina
May, Sarah C.
Anderson, Ryan M.
Samala, Niharika
Mirmira, Raghavendra G.
author_sort Basha, Amina
collection PubMed
description Nonalcoholic fatty liver disease (NAFLD) is a range of pathologies arising from fat accumulation in the liver in the absence of excess alcohol use or other causes of liver disease. Its complications include cirrhosis and liver failure, hepatocellular carcinoma, and eventual death. NAFLD is the most common cause of liver disease globally and is estimated to affect nearly one-third of individuals in the United States. Despite knowledge that the incidence and prevalence of NAFLD are increasing, the pathophysiology of the disease and its progression to cirrhosis remain insufficiently understood. The molecular pathogenesis of NAFLD involves insulin resistance, inflammation, oxidative stress, and endoplasmic reticulum stress. Better insight into these molecular pathways would allow for therapies that target specific stages of NAFLD. Preclinical animal models have aided in defining these mechanisms and have served as platforms for screening and testing of potential therapeutic approaches. In this review, we will discuss the cellular and molecular mechanisms thought to contribute to NAFLD, with a focus on the role of animal models in elucidating these mechanisms and in developing therapies.
format Online
Article
Text
id pubmed-10298283
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102982832023-06-28 Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models Basha, Amina May, Sarah C. Anderson, Ryan M. Samala, Niharika Mirmira, Raghavendra G. Int J Mol Sci Review Nonalcoholic fatty liver disease (NAFLD) is a range of pathologies arising from fat accumulation in the liver in the absence of excess alcohol use or other causes of liver disease. Its complications include cirrhosis and liver failure, hepatocellular carcinoma, and eventual death. NAFLD is the most common cause of liver disease globally and is estimated to affect nearly one-third of individuals in the United States. Despite knowledge that the incidence and prevalence of NAFLD are increasing, the pathophysiology of the disease and its progression to cirrhosis remain insufficiently understood. The molecular pathogenesis of NAFLD involves insulin resistance, inflammation, oxidative stress, and endoplasmic reticulum stress. Better insight into these molecular pathways would allow for therapies that target specific stages of NAFLD. Preclinical animal models have aided in defining these mechanisms and have served as platforms for screening and testing of potential therapeutic approaches. In this review, we will discuss the cellular and molecular mechanisms thought to contribute to NAFLD, with a focus on the role of animal models in elucidating these mechanisms and in developing therapies. MDPI 2023-06-10 /pmc/articles/PMC10298283/ /pubmed/37373143 http://dx.doi.org/10.3390/ijms24129996 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Basha, Amina
May, Sarah C.
Anderson, Ryan M.
Samala, Niharika
Mirmira, Raghavendra G.
Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models
title Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models
title_full Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models
title_fullStr Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models
title_full_unstemmed Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models
title_short Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models
title_sort non-alcoholic fatty liver disease: translating disease mechanisms into therapeutics using animal models
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298283/
https://www.ncbi.nlm.nih.gov/pubmed/37373143
http://dx.doi.org/10.3390/ijms24129996
work_keys_str_mv AT bashaamina nonalcoholicfattyliverdiseasetranslatingdiseasemechanismsintotherapeuticsusinganimalmodels
AT maysarahc nonalcoholicfattyliverdiseasetranslatingdiseasemechanismsintotherapeuticsusinganimalmodels
AT andersonryanm nonalcoholicfattyliverdiseasetranslatingdiseasemechanismsintotherapeuticsusinganimalmodels
AT samalaniharika nonalcoholicfattyliverdiseasetranslatingdiseasemechanismsintotherapeuticsusinganimalmodels
AT mirmiraraghavendrag nonalcoholicfattyliverdiseasetranslatingdiseasemechanismsintotherapeuticsusinganimalmodels